Vico Therapeutics Funding News – Netherlands-based Vico Therapeutics Raises €11.5M Additional Series B Funding

Read also - Curve Funding News – UK-based Curve Secures Funding from Samsung Next

Previously Vico Therapeutics B.V. secured $60 million (€54 million) Series B financing led by new investor Ackermans & van Haaren (AvH) with existing co-leads Droia Ventures, EQT Life Sciences, and Kurma Partners along with prior investors Polaris Partners, Pureos Bioventures and Eurazeo in january 2024.

Read also - EpilepsyGTx Funding News – UK-based EpilepsyGTx Raises $10Mn Funding led by the UCL Technology Fund

Catello Somma, Partner at Seroba, comments, “We are extremely proud to support Vico in this financing round and join the existing investors. The growth capital will help the Company bolster its clinical programs to deliver life-changing outcomes for patients with polyQ diseases, such as SCA and Huntington’s. We are excited to partner with Vico and its remarkable team as the Company advances its programs.”

Daniel Parera and Jean-Francois Rivassou, Partners at Kurma, comment, “Vico is another very nice example of a company where Kurma Partners acted as a co-founding investor (Rémi Droller on behalf of Kurma Biofund III alongside EQT Life Sciences) that has progressed into clinical development, where Kurma Growth Opportunities Fund can add further support to the Company and its experienced management team in the continuation of Vico’s path together with existing investors.”

About Vico Therapeutics

Founded in 2019. Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe neurological diseases. Its lead product candidate, VO659, is currently in Phase 1/2a clinical development for the treatment of spinocerebellar ataxia types 3 and 1 and Huntington’s disease and is the only ASO in the clinic that targets the underlying CAG repeat expansions that cause all nine known polyglutamine diseases.

Vico’s research platform designs fit-for-purpose ASOs by applying precision chemistry with mechanisms of action ideally suited to target genetic neurological diseases.